ATS 2019 Virtual Final Program

110 The Prevalence and Progression of Early Interstitial Lung Disease in First-Degree Relatives of Patients with Familial Interstitial Pneumonia/ J.C. Hewlett, C. Markin, K. Douglas, G. Ding, D. Mitchell, S. Reiss, J. Worrell, A. Guttentag, W.E. Lawson, J. Phillips, III, J.D. Cogan, L.R. Young, J.E. Loyd, T.S. Blackwell, J. Kropski, Nashville, TN, p.A7136 111 Subacute Exacerbation of Idiopathic Pulmonary Fibrosis: Incidence, Characteristics and Outcomes/ J. Caliez, L. Sesé, V. Cottin, Z. Carton, M. Didier, D. Israël-Biet, B. Crestani, J. Cadranel, B. Wallaert, A. Tazi, B. Maitre, G. Prévot, S. Marchand-Adam, S. Guillot-Dudoret, A. Nardi, S. Dury, V. Giraud, A. Gondouin, K. Juvin, R. Borie, M. Wislez, D. Valeyre, H. Nunes, Bobigny, France p.A7137 112 In Treated Patients with Idiopathic Pulmonary Fibrosis Hiatus Hernia but Not Acid Reflux Predicts Disease Progression and Survival/ J. Mackintosh, S. Desai, H.I. Adamali, K. Patel, F. Chua, E.A. Renzoni, M. Kokosi, V. Kouranos, G. Margaritopoulos, A. Wells, P.L. Molyneaux, S. Kumar, T.M. Maher, P.M. George, London, United Kingdom, p.A7138 113 Predictors of Mortality on Cardiopulmonary Exercise Testing in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)/ C. Boily-Daoust, J. Chalaoui, J. Morisset, C. Poirier, B.P. Dubé, Montreal, Canada, p.A7139 114 Physiological Response to Exercise and Vital Prognosis in Patients with Combined Pulmonary Fibrosis and Emphysema: Comparison to Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis/ C. Boily-Daoust, J. Chalaoui, C. Poirier, J. Morisset, B.-P. Dubé, Montreal, Canada, p.A7140 115 Sex Hormones and Interstitial Lung Abnormalities in a Population-Based Cohort: The Multi-Ethnic Study of Atherosclerosis/ T. Zaman, P. Ouyang, E. Michos, C.E. Ventetuolo, A. Podolanczuk, S.M. Kawut, G. Raghu, K.D. Hinckley Stukovsky, R.G. Barr, J.S. Lee, D.J. Lederer, Aurora, CO, p.A7141 116 Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality/ R.K. Putman, G. Gudmundsson, G.T. Axelsson, T. Hida, O. Honda, T. Araki, M. Yanagawa, M. Nishino, E.R. Miller, G. Eiriksdottir, E.F. Gudmundsson, N. Tomiyama, H. Honda, I.O. Rosas, G.R. Washko, M.H. Cho, D.A. Schwartz, V. Gudnason, H. Hatabu, G.M. Hunninghake, Boston, MA, p.A7142 117 Frailty Is Associated with Decreased Pulmonary Function in Interstitial Lung Disease/ S. Bhorade, R. Jablonski, J. Lee, M. Masihi, A. Ansari, R. Tomic, J.E. Dematte, Chicago, IL, p.A7143 118 Prevalence and Prognostic Impact of Various Malignant Disease in Patients with Idiopathic Pulmonary Fibrosis/ H. Lee, J. Cho, J. Lee, Y.S. Park, C.-H. Lee, S.-M. Lee, J.-J. Yim, C.-G. Yoo, Y.W. Kim, S.K. Han, S.M. Choi, Seoul, Korea, Republic of, p.A7144 119 Health Related Quality of Life and Biomarker Levels in Patients with Idiopathic Pulmonary Fibrosis/ S. Kay, P.-V. Mari, M. Xia, S. Murray, E. Belloli, M.L. Salisbury, J.S.V. Sheth, B. Wang, C. Holtze, F.J. Martinez, K.R. Flaherty, E.S. White, Ann Arbor, MI, p.A7145 120 Single- Versus Multi-Component Physical Performance Measures and Mortality in Idiopathic Pulmonary Fibrosis/ C.M. Nolan, M. Maddocks, T. Maher, S. Patel, R.E. Barker, S.E. Jones, S.C. Wynne, J.A. Walsh, P.M. George, P. Cullinan, W.D.C. Man, Harefield, United Kingdom, p.A7146 121 The Effects of Tobacco Smoking Intensity and Cessation on Idiopathic Pulmonary Fibrosis Incidence and Progression/ R. McKnight, L.H. Lancaster, J. Kropski, W. Mason, Nashville, TN, p.A7147 122 Minimally Important Difference (MID) for the European Quality of Life - 5 Dimensions (EQ-5D) in Fibrotic Interstitial Lung Disease/ A.P.Y. Tsai, S.A. Hur, D. Assayag, K.A.M. Johannson, J. Morisset, C.D. Fell, J.H. Fisher, H. Manganas, S. Shapera, G.P. Cox, A.S. Gershon, N. Hambly, N. Khalil, M. Sadatsafavi, T.M. To, P. Wilcox, A.J. Halayko, M.R.J. Kolb, C.J. Ryerson, Vancouver, Canada, p.A7148 123 Predictors and Pathology of Acute Exacerbation of Idiopathic Pulmonary Fibrosis/ Y. Dotan, W.B. Shapiro, A. Aneja, Z. Hauqing, C.A. Dass, K. Shenoy, F.C. Cordova, G.J. Criner, A.J. Mamary, Bethlehem, PA, p.A7149 124 Improving Care of Patients with IPF: A Collaborative Approach/ R. O’Beirne, D. Blatherwick, K. Lucero, J.A. De Andrade, B. Stofan, M. Morris, Birmingham, AL, p.A7150 CLINICAL • TRANSLATIONAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION D104 CRITICAL CARE: A FINE BALANCE - SEPSIS DEFINITIONS, OUTCOMES AND EPIDEMIOLOGY 1:30 p.m. - 3:30 p.m. OMNI DALLAS DOWNTOWN Trinity Ballroom 5-7 (Level 3) Abstract Summaries 1:30-2:00 Viewing/Discussion 2:00-3:30 Chairing: V. Liu, MD, MS, Oakland, CA M.M. Churpek, MD, MPH, PhD, ATSF, Chicago, IL N. Meyer, MD, MS, Philadelphia, PA 1001 Global Trends in Sepsis Mortality Between 2001 and 2015: A Comparative Analysis of Administrative Sepsis Definitions/ J.D. Salciccioli, M. Komorowski, J. Shalhoub, P.F. Clardy, D. Marshall, Cambridge, MA, p.A7151 1002 Epidemiology and Outcomes of Cancer-Related and Non-Cancer-Related U.S. Sepsis Hospitalizations/ M. Hensley, H.C. Prescott, Ann Arbor, MI, p.A7152 1003 Epidemiology of Surgical Amputation After Sepsis/ K. Reitz, J. Kennedy, H.B. Gershengorn, T.D. Girard, M.D. Neal, H.C. Prescott, M.R. Rosengart, V. Talisa, E. Tzeng, H. Wunsch, S. Yende, D.C. Angus, C.W. Seymour, Pittsburgh, PA, p.A7153 ATS 2019 • Dallas, TX 384 WEDNESDAY • MAY 22